Human rhinovirus cDNA and Recombinant Antigen

Human rhinovirus is a type of virus that causes the common cold. It is highly contagious and spreads easily through droplets generated when an infected person sneezes or coughs. The symptoms of a rhinovirus infection include runny nose, sneezing, coughing, and sore throat. There is no specific treatment for rhinovirus, but over-the-counter medications and rest can help alleviate symptoms.

The human rhinovirus antigen is a component of the rhinovirus that elicits an immune response. It is recognized by the immune system as foreign, triggering the production of antibodies that help protect against future infections with the same virus. Antigens can be used in diagnostic tests to identify the presence of a specific virus, or as part of a vaccine to prevent infection. In the case of the human rhinovirus, a vaccine has not yet been developed.

The human rhinovirus genome is the complete genetic material of the virus. It consists of a single strand of RNA and is approximately 7.2 kilobases in length. The genome encodes for all the proteins needed for the virus to replicate and cause infection. Understanding the human rhinovirus genome is important for the development of treatments and vaccines for the common cold.

Human rhinovirus is a common virus that causes the common cold. It belongs to the family Picornaviridae and the genus Enterovirus. There are over 100 serotypes of human rhinovirus, with serotypes 16, B1,2, and 89 being some of the known serotypes.

The virus has a single-stranded positive-sense RNA genome which encodes a polyprotein that is subsequently cleaved by viral proteases to produce the individual viral proteins. The major structural proteins of human rhinovirus include VP1, VP2, VP3, and VP4, which form the viral capsid. VP0 is a precursor protein that is cleaved to produce VP2 and VP4.

Other non-structural proteins include 2A and 3C proteases, which are responsible for processing the viral polyprotein, as well as VP1, 2B, and 2C, which are involved in viral replication and assembly.

The VP1 protein is the most variable and immunogenic, and it is often used to distinguish between different serotypes of human rhinovirus. Overall, understanding the structure and function of these viral proteins is important for developing antiviral drugs and vaccines to combat the common cold.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.